Evogene

EVGN

Market cap $11.3M

REHOVOT, Israel , Aug. 28, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology and chemistry company, today announced that Ofer Haviv, Evogene's President and CEO, will present at the H.C.

Evogene Ltd. (NASDAQ:EVGN ) Q2 2025 Earnings Conference Call August 19, 2025 9:00 AM ET Company Participants Ofer Haviv - CEO, President & Director Yaron Eldad - Chief Financial Officer Unidentified Company Representative Welcome to Evogene's Second Quarter 2025 Results Conference Call.

Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated statements of profit and loss for the first half of 2025. Their results are included under the line titled - "Loss from operations held for sale, net".

A failure in metabolite breakdown leads to their ordered self-assembly into pathological aggregates, such as in Tyrosinemia   and Gout. REHOVOT, Israel , Aug. 12, 2025 /PRNewswire/ -- Evogene Ltd.

Zoom conference call scheduled for August 19, 2025, 9:00 AM ET REHOVOT, Israel , July 29, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Tuesday , August 19 , 2025.

REHOVOT, Israel , July 8, 2025 /PRNewswire/ -- Evogene Ltd.  (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company utilizing cutting-edge artificial intelligence and predictive biology to drive innovation in life-science product development, today announced the successful completion and closing of the previously disclosed transaction involving the divestiture of the majority of the activities and assets of its ag-biologicals subsidiary, Lavie Bio Ltd.

The new model addresses the challenge of identifying novel small molecules that meet multiple product criteria, an essential requirement for pharma and agriculture applications REHOVOT, Israel , June 10, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing life-science product discovery and development, today announced the completion of its generative AI foundation model, version 1.0, for small molecule design, developed in collaboration with Google Cloud.

Evogene Ltd. (NASDAQ:EVGN ) Q1 2025 Earnings Conference Call May 21, 2025 9:00 AM ET Company Participants Ofer Haviv - President and Chief Executive Officer Yaron Eldad - Chief Financial Officer Operator Welcome to Evogene's First Quarter 2025 Results Conference Call.

Conference call and webcast: today, May 21, 2025, 9:00 am ET Financial Highlights: In the first quarter of 2025, total revenues were approximately $2.4 million, compared to approximately $4.2 million in the first quarter of 2024. The first quarter of 2024 revenues included license fee payments totaling $3.5 million - $2.5 million from Lavie Bio's license fee under its collaboration with Corteva, and $1.0 million from AgPlenus' license fee under its collaboration with Bayer.

Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel , May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025.